A new safety layer aims to help robots sense people in real time without slowing production
Updated
February 13, 2026 10:44 AM

An industrial robot in a factory. PHOTO: UNSPLASH
Algorized has raised US$13 million in a Series A round to advance its AI-powered safety and sensing technology for factories and warehouses. The California- and Switzerland-based robotics startup says the funding will help expand a system designed to transform how robots interact with people. The round was led by Run Ventures, with participation from the Amazon Industrial Innovation Fund and Acrobator Ventures, alongside continued backing from existing investors.
At its core, Algorized is building what it calls an intelligence layer for “physical AI” — industrial robots and autonomous machines that function in real-world settings such as factories and warehouses. While generative AI has transformed software and digital workflows, bringing AI into physical environments presents a different challenge. In these settings, machines must not only complete tasks efficiently but also move safely around human workers.
This is where a clear gap exists. Today, most industrial robots rely on camera-based monitoring systems or predefined safety zones. For instance, when a worker steps into a marked area near a robotic arm, the system is programmed to slow down or stop the machine completely. This approach reduces the risk of accidents. However, it also means production lines can pause frequently, even when there is no immediate danger. In high-speed manufacturing environments, those repeated slowdowns can add up to significant productivity losses.
Algorized’s technology is designed to reduce that trade-off between safety and efficiency. Instead of relying solely on cameras, the company utilizes wireless signals — including Ultra-Wideband (UWB), mmWave, and Wi-Fi — to detect movement and human presence. By analysing small changes in these radio signals, the system can detect motion and breathing patterns in a space. This helps machines determine where people are and how they are moving, even in conditions where cameras may struggle, such as poor lighting, dust or visual obstruction.
Importantly, this data is processed locally at the facility itself — not sent to a remote cloud server for analysis. In practical terms, this means decisions are made on-site, within milliseconds. Reducing this delay, or latency, allows robots to adjust their movements immediately instead of defaulting to a full stop. The aim is to create machines that can respond smoothly and continuously, rather than reacting in a binary stop-or-go manner.
With the new funding, Algorized plans to scale commercial deployments of its platform, known as the Predictive Safety Engine. The company will also invest in refining its intent-recognition models, which are designed to anticipate how humans are likely to move within a workspace. In parallel, it intends to expand its engineering and support teams across Europe and the United States. These efforts build on earlier public demonstrations and ongoing collaborations with manufacturing partners, particularly in the automotive and industrial sectors.
For investors, the appeal goes beyond safety compliance. As factories become more automated, even small improvements in uptime and workflow continuity can translate into meaningful financial gains. Because Algorized’s system works with existing wireless infrastructure, manufacturers may be able to upgrade machine awareness without overhauling their entire hardware setup.
More broadly, the company is addressing a structural limitation in industrial automation. Robotics has advanced rapidly in precision and power, yet human-robot collaboration is still governed by rigid safety systems that prioritise stopping over adapting. By combining wireless sensing with edge-based AI models, Algorized is attempting to give machines a more continuous awareness of their surroundings from the start.
Keep Reading
How a Korean biotech startup is using AI to move drug discovery from trial-and-error to precision design

A close up of a protein structure model. PHOTO: UNSPLASH
For decades, drug discovery has relied on trial and error, with scientists testing thousands of molecules to find one that works. Galux, a South Korean biotech startup, is changing that by using AI to design proteins from scratch. This method, called “de novo” design, makes it possible to build precise new therapies instead of searching through existing ones.
The company recently announced a US$29 million Series B funding round, bringing its total capital to US$47 million.This significant investment attracted a substantial roster of institutional backers, including the Korea Development Bank (KDB), Yuanta Investment, SL Investment and NCORE Ventures. These firms joined existing investors such as InterVest, DAYLI Partners and PATHWAY Investment, as well as new participants including SneakPeek Investments, Korea Investment & Securities and Mirae Asset Securities.
At the core of the company’s work is a platform called GaluxDesign. Unlike many AI tools that only predict how existing proteins fold, this system uses deep learning and physics to create entirely new therapeutic antibodies. This “from scratch” approach lets the team go after so-called “undruggable” proteins. These are targets that traditional small-molecule drugs can’t reach because they lack clear binding pockets. By designing proteins to fit these complex shapes, Galux aims to unlock treatments that have stayed out of reach for decades. And that’s exactly why investors are paying attention.
The pharmaceutical industry is actively looking for faster and more efficient ways to develop new drugs, and Galux is built for exactly that. The company connects its AI platform directly to its own wet lab, where designs can be tested in real time. Each result feeds straight back into the system, sharpening the next round of models. This continuous loop speeds up discovery and improves precision at every step. It’s also why partners like Celltrion, LG Chem and Boehringer Ingelheim are already working with Galux.
Galux is no longer just trying to make drugs that stick to a target. The company now wants its AI to design medicines that actually work in the body and can be made at scale. In simple terms, a drug has to do more than bind to a disease—it must be stable, safe and strong enough to change how the illness behaves. Galux is moving into tougher targets such as ion channels and GPCRs. These play key roles in heart function and sensory signals. Ultimately, the goal is to show that AI-driven design can turn complex biology into real treatments. And instead of hunting blindly for a solution, the team is building exactly what they need.